Total Flavonoids of Rhizoma Drynariae Treat Osteoarthritis by Inhibiting Arachidonic Acid Metabolites Through AMPK/NFκB Pathway
Guang-Yao Chen,Xiao-Yu Liu,Xue-Er Yan,XinBo Yu,Yi Liu,Jing Luo,Qing-Wen Tao
DOI: https://doi.org/10.2147/jir.s418345
IF: 4.5
2023-09-20
Journal of Inflammation Research
Abstract:Guang-Yao Chen, 1, 2, &ast Xiao-Yu Liu, 3, &ast Xue-Er Yan, 4, &ast XinBo Yu, 1, 2 Yi Liu, 5 Jing Luo, 1, 2 Qing-Wen Tao 1, 2 1 Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, People's Republic of China; 2 Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, People's Republic of China; 3 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 4 Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China; 5 Humanities School, Beijing University of Chinese Medicine, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qing-Wen Tao, Email Objective: Previous clinical studies have found that total flavonoids of Rhizoma Drynariae (TFRD) have a good therapeutic effect on osteoarthritis (OA), but its therapeutic mechanism needs further research. Methods: OA rat model was established by Hulth method and was intervened by TFRD. Pathological assessments were conducted to assess the protective effect of TFRD on cartilage. Serum metabolomics and network pharmacology were detected to predict the mechanism of TFRD treating OA. In further experiments, molecular biology experiment was carried out to confirm the predicted mechanisms in vivo and in vitro. Results: TFRD can effectively reduce chondrocyte apoptosis and cartilage degeneration in OA model rats. Serum metabolomics revealed that the intervention effect may be closely related to arachidonic acid metabolism pathway. Network pharmacologic prediction showed that COX-2 was the key target of TFRD in treating OA, and its mechanism might be related with NFκB, apoptosis, AMPK and arachidonic acid metabolism pathway. In vivo experiments indicated that TFRD can inhibit the abnormal expression of COX-2 mRNA in OA model rats. In the in vitro studies, the expression of COX-2 mRNA and protein increased, AMPK phosphorylation was inhibited, and NFκB signaling pathway was activated in IL-1β-induced chondrocytes, and these changes can be reversed by TFRD. After the activation of AMPK signaling pathway or the block-down of NFκB signaling pathway, the effect of TFRD on COX-2 mRNA expression was significantly weakened. Conclusion: TFRD can inhibit COX-2-mediated arachidonic acid metabolites, and its mechanism is closely related to AMPK/NFκB pathway, which may be a key mechanism in the treatment of OA. Keywords: total flavonoids of Rhizoma Drynariae, osteoarthritis, network pharmacology, serum metabolomics, cyclooxygenase-2, AMPK/NFκB pathway Osteoarthritis (OA) is a common degenerative joint disease characterized by chronic pain and ambulation limitation, affecting about 250 million people worldwide. 1 With increased aging population, the OA incidence rapidly increases and OA has become a major cause of disability. 2,3 The morbidity of OA is closely related to articular cartilage, synovium, subchondral bone and surrounding muscles and ligaments, and cartilage plays a critical role in the pathogenesis of OA. 4–7 The senescence of chondrocytes, joint trauma and altered structural mechanics are the most common reasons in the development of OA. 1,8 In the initial phase of OA, a chronic inflammatory response in chondrocytes promotes the secretion of a mass of matrix hydrolytic enzymes, leading to matrix imbalance and cartilage degradation. 9 In terms of treatment, NSAIDs possess anti-inflammatory and analgesic properties, and are recommended as a first-line treatment in most clinical guidelines. 10 But the long-term of use NSAIDs is a major cause of gastrointestinal ulcers and hemorrhage. 11 Glucocorticoids administered intra-articularly can provide rapid relief of inflammatory responses in joints, but repeated administration may induce a series of adverse reactions. 12 Glucosamine and chondroitin sulphate have been used in the treatment of OA, but their clinical efficacy is questionable. 13,14 As a result, more safe and effective drugs have remained to be developed, but in recent years a number of drug developments for OA have failed. 15 The search for effective ingredients from natural compounds for the treatment of OA has become a research hotspot today. 16,17 Various flavonoids extracted from plants, such as quercetin, luteolin and kaempferol, are considered candidates for disease-modifying anti-OA drugs by virtue of their anti-inflammatory and chondroprote -Abstract Truncated-
immunology